necitumumab (Portrazza)

Indications

• treatment of metastatic squamous cell lung cancer in treatment niave patients

Dosage

Injection: 16 mg/mL (50 mL)

Adverse effects

• most common
  • skin rash
  • hypomagnesemia* (can be fatal)

* boxed warning

• cardiac arrest, sudden death, hypomagnesemia

• drug adverse effects of tyrosine kinase inhibitor(s)
• drug adverse effects of EGF receptor inhibitors
• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• monoclonal antibody that blocks activity of EGFR

More general terms

• antineoplastic monoclonal antibody
• EGF receptor (EGFR) inhibitor